RXRX Recursion Pharmaceuticals Inc

$RXRX Someone is scared… 🚀 Short interest plunged 20.8M shares (−11.63%), from 178.7M to 157.9M as of Sept. 30! Days to cover dropped from 12.56 to 6.13. Bulls gaining momentum ahead of November’s REC-4881 catalyst! 🔥

🚀 $RXRX could be one of the most underrated AI opportunities in biotech. Most investors are focused on AI chatbots and chips. Meanwhile, Recursion is using AI to tackle something far more valuable: discovering new medicines. This isn't just AI hype. Recursion is running millions of real biological experiments, building massive proprietary datasets, and using AI to discover disease targets and design new drugs. ✅ Genentech advancing an AI-discovered neuroscience target ✅ Promising Phase 2 results from REC-4881 ✅ AI-driven drug design accelerating discovery ✅ Partnerships with major pharmaceutical companies ✅ A continuously improving AI platform powered by real laboratory data The real opportunity isn't just one successful drug. It's building an AI-powered discovery engine capable of producing many. AI is transforming software. $RXRX is betting it can transform medicine. I'm bullish on the long-term potential. 🔥 #$RXRX #AI #Biotech #DrugDiscovery

$RXRX Are the remaining short sellers comfortable holding through November 2? Approximately 158 million shares are STILL short. That’s an enormous amount of potential future buying if shorts decide to cover.

$RXRX Been saying this for a long time. Patience is the key. Not talking about bullshit actions at this stage ups/downs

$RXRX those institutional loading was on point. 3 tripple bottom touched. They are going to make money by prefront loading. Just waiting for the weekly candle to close before ER.

$RXRX just the beginning of ai drug discovery mania, isomorphic 50 bln valuation. Recursion more mature than peers, if rec 4881 gets fda alignment than 0 to 100 real quick . Think of quantum stoks summer 24, they were under 1 and mostly all min 10x now. And ai drug discovery is going to get additional government attention because this sector will not get any negative ai news . My guess early next year either anthropic or isomorphic will buy them , maybe the latter because they are more clinical focused. Anthropic buyout maybe not easy . I think isomorphic lab will buy rxrx next year, 40 bln loading. Game on guys . Why 40 bln ? They are the most complete ai drug discovery company . Think of tesla amazon meta quantum in early days, rxrx has the potential to be there, so 40 bln seems cheap. Isomorphic talks about curing all diseases , this will 🚀 patient for few more months. Hope nov 2 doesnt disappoint.

$RXRX Wow, since when did we get such foolish bears posting here? Cathie Wood's ARK reportedly purchased approximately 1.9 million RXRX shares yesterday, following another reported purchase of 1.5 million earlier in the week.

$RXRX $RXRX 🚀 Cathie Wood is LOADED through ARKK + ARKG. Roche/Genentech is validating the science. AI + BIOLOGY is becoming the next serious growth trade. $RXRX has the setup to become THE flagship name. Still early. Still misunderstood. Still cheap. When Wall Street finally connects the dots, the chase could be violent. $RXRX 🐂🔥 $SPY $MRNA

$RXRX Can’t keep up with these daily swings 😅 Swing closed, cash rebuilt, core locked in the vault 🔒 Waiting for clinical results.

$RXRX Hope you got your Bags. Next week is going to be wild. Cheers folks. Happy Thanksgiving to all the Canucks.

$RXRX TEMPUS AI — ANOTHER MAJOR PARTNERSHIP Tempus AI and Recursion Pharmaceuticals have strengthened their partnership through November 2029, with Recursion committing $42.X million to Tempus for continued access to Tempus’ multimodal oncology data. As part of the expanded agreement, Tempus receives a license to Recursion’s proprietary RNA Foundation Model, giving Tempus access to the same advanced RNA technology Recursion has developed and uses in its AI-driven drug discovery platform. This brings together Tempus’ massive clinical and genomic data ecosystem with Recursion’s advanced RNA AI technology. Another significant step forward for AI-driven precision medicine, oncology and drug discovery.

$RXRX There is an AI driven Biotech race going on behind the scenes. Some of the big drug companies are trying to forego drug discovery and license platforms from China. The powers that be are aware and can’t let that happen. The cost of healthcare is rising too fast. We have to shift and remain top in drug discovery and in the future move towards cures and not treatments.. RXRX sits in the sweet spot ..

$RXRX 8,4m shares traded in 50 minutes… If volume keeps up like this… not 🚀 we will take the 🛸 Shorts having a hard day for sure 😂

$RXRX If ARK is buying, they have done their DD and know something from insider that folks in this chat group don’t. Be patient and you will get rewarded. If you are here for Pennie’s this stock is not for you. With more than 30% float short even the PR for the ER will send this 20-30% up anytime

$RXRX 👀 Antonio Linares names Recursion as his pick for the biological data layer—mapping cellular changes to uncover disease targets. The bullish thesis: proprietary experiments feed reusable data into AI models, creating a potential discovery advantage across programs.

$RXRX do not buy options on biotechnology company, buy shares instead. The market maker will clear out those who bought options

$RXRX The story isn’t just the buying. It’s that all this selling hasn’t knocked RXRX back down. 63 million volume

$RXRX With this kind of volume the MM's averaged up their short positions then hit it big time with NAKED CALL SALES. Weak hands are already out so just be patient. Someone rocked it up this morning and they will be back

$RXRX 1 day closer to 2 nov. It dosent matter what shorts do. All comes down to what the company actually have that day to present… That will tell the direction 🍻🦾

$RXRX Folks, Roche has been building their AI presence. They bought PathAI for a billion. This is worth 10 Billion right now & more. GN🍺